Skip to main content

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.

Publication ,  Journal Article
Gray, GE; Mayer, KH; Elizaga, ML; Bekker, L-G; Allen, M; Morris, L; Montefiori, D; De Rosa, SC; Sato, A; Gu, N; Tomaras, GD; Tucker, T ...
Published in: Clin Vaccine Immunol
June 2016

A phase I safety and immunogenicity study investigated South African AIDS Vaccine Initiative (SAAVI) HIV-1 subtype C (HIV-1C) DNA vaccine encoding Gag-RT-Tat-Nef and gp150, boosted with modified vaccinia Ankara (MVA) expressing matched antigens. Following the finding of partial protective efficacy in the RV144 HIV vaccine efficacy trial, a protein boost with HIV-1 subtype C V2-deleted gp140 with MF59 was added to the regimen. A total of 48 participants (12 U.S. participants and 36 Republic of South Africa [RSA] participants) were randomized to receive 3 intramuscular (i.m.) doses of SAAVI DNA-C2 of 4 mg (months 0, 1, and 2) and 2 i.m. doses of SAAVI MVA-C of 1.45 × 10(9) PFU (months 4 and 5) (n = 40) or of a placebo (n = 8). Approximately 2 years after vaccination, 27 participants were rerandomized to receive gp140/MF59 at 100 μg or placebo, as 2 i.m. injections, 3 months apart. The vaccine regimen was safe and well tolerated. After the DNA-MVA regimen, CD4(+) T-cell and CD8(+) T-cell responses occurred in 74% and 32% of the participants, respectively. The protein boost increased CD4(+) T-cell responses to 87% of the subjects. All participants developed tier 1 HIV-1C neutralizing antibody responses as well as durable Env binding antibodies that recognized linear V3 and C5 peptides. The HIV-1 subtype C DNA-MVA vaccine regimen showed promising cellular immunogenicity. Boosting with gp140/MF59 enhanced levels of binding and neutralizing antibodies as well as CD4(+) T-cell responses to HIV-1 envelope. (This study has been registered at ClinicalTrials.gov under registration no. NCT00574600 and NCT01423825.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Vaccine Immunol

DOI

EISSN

1556-679X

Publication Date

June 2016

Volume

23

Issue

6

Start / End Page

496 / 506

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vaccinia
  • Vaccines, DNA
  • Vaccination
  • Time Factors
  • South Africa
  • Microbiology
  • Male
  • Injections, Intramuscular
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gray, G. E., Mayer, K. H., Elizaga, M. L., Bekker, L.-G., Allen, M., Morris, L., … Williamson, A.-L. (2016). Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol, 23(6), 496–506. https://doi.org/10.1128/CVI.00717-15
Gray, Glenda E., Kenneth H. Mayer, Marnie L. Elizaga, Linda-Gail Bekker, Mary Allen, Lynn Morris, David Montefiori, et al. “Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.Clin Vaccine Immunol 23, no. 6 (June 2016): 496–506. https://doi.org/10.1128/CVI.00717-15.
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, et al. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 Jun;23(6):496–506.
Gray, Glenda E., et al. “Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.Clin Vaccine Immunol, vol. 23, no. 6, June 2016, pp. 496–506. Pubmed, doi:10.1128/CVI.00717-15.
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson A-L. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 Jun;23(6):496–506.

Published In

Clin Vaccine Immunol

DOI

EISSN

1556-679X

Publication Date

June 2016

Volume

23

Issue

6

Start / End Page

496 / 506

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Young Adult
  • Vaccinia
  • Vaccines, DNA
  • Vaccination
  • Time Factors
  • South Africa
  • Microbiology
  • Male
  • Injections, Intramuscular